Loading stock data…
$2.30+0.05 (+2.33%)
BioStem Technologies, Inc.
BioStem Technologies, Inc. in the Healthcare sector is trading at $2.30 with a market capitalization of $71M. Wall Street consensus targets $7.00 (1 analysts), implying a +204.5% move over the next 12 months. The stock is currently near its 52-week low of $2.13, remaining 47.4% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|
| Total Revenue | $7.90M↓ | $10.47M↓ | $10.96M↓ | $102.87M↑ | $18.41M |
| Gross Profit | $4.84M↓ | $9.27M↓ | $10.28M↓ | $99.34M↑ | $14.17M |
| Operating Income | -$8.40M↓ | $1.45M↑ | $112,759↓ | $8.48M↓ | $9.29M |
| Net Income | -$8.97M↓ | $761,052↑ | $10,613↓ | $15.52M↑ | $6.82M |
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix c...